![NA masthead new 1](https://prodcraftsa01.blob.core.windows.net/assets/products/neurology-alert/_contentImage/NA_masthead_new_1.png)
Neurology Alert – February 1, 2009
February 1, 2009
View Issues
-
Pathological Gambling in Parkinson's Disease: New Insights from Functional Neuroimaging
Pathological gambling related to dopamine replacement therapy in Parkinson's disease is associated with overactivity of a right hemisphere network that includes regions involved in impulse control, reward, motivation, and memory. -
Stroke Recurrence in Patent Formen Ovale (PFO)
In this study, there is no correlation between the risk of recurrent stroke and the size of a PFO, the magnitude of the right-to-left shunt, or the presence of an atrial septal aneurysm. -
Do Statins Reduce the Risk of Future Alzheimer-type Dementia?
Statin use, regardless of drug type, reduces the risk of dementia in later life. -
Is Earlier Treatment of Parkinson's Disease Better?
This is an open label extension of 306 subjects from a previously reported delayed-start phase III clinical trial of rasagiline in early Parkinson's disease. Clinical benefit observed at one year in the early vs. delayed-start arm was maintained over an average 3.6 ± 2.1 years observation, raising the question of whether earlier intervention with rasagiline results in better outcomes. -
Nerve and Muscle Biopsy for the Diagnosis of Vasculitis
Biopsy of the clinically affected nerve gives the highest yield for the diagnosis of vasculitic neuropathy. -
Bilateral Subthalamic Stimulation and Cognitive-Motor Performance in Parkinson's Disease Patients
Spreading of stimulation current to non-motor regions of the subthalamic nucleus (STN) or surrounding fiber tracts could be responsible for cognitive declines after STN deep brain stimulation (DBS), especially during bilateral stimulation and during complex cognitive-motor dual task. -
Pharmacology Watch
Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions. -
Clinical Briefs in Primary Care Supplement